TABLE 2.
Clinical characteristics of patients
| Clinical characteristics | Number of patients | P | ||
|---|---|---|---|---|
| Total (n = 87) | taxA (n = 40) | taxB (n = 47) | ||
| Sex | ||||
| M | 38 | 19 | 19 | .328 |
| F | 49 | 21 | 28 | |
| Age | ||||
| <70 | 46 | 21 | 25 | .560 |
| ≥70 | 41 | 19 | 22 | |
| Median (range) | 69 (35‐90) | 69 (53‐90) | 69 (35‐90) | |
| Clinical subtype | ||||
| Acute | 62 | 27 | 35 | .477 |
| Lymphoma | 12 | 7 | 5 | |
| Unfavorable chronic | 2 | 0 | 2 | |
| Disease progression from indolent form | 11 | 6 | 5 | |
| PS | ||||
| 0‐1 | 40 | 17 | 23 | .667 |
| 2‐4 | 47 | 23 | 24 | |
| Ann Arbor stage | ||||
| I‐II | 5 | 1 | 4 | .227 |
| III‐IV | 81 | 39 | 42 | |
| Unevaluable | 1 | 0 | 1 | |
| LDH (U/L) | ||||
| <230 | 6 | 2 | 4 | .683 |
| ≥230 | 81 | 38 | 43 | |
| Serum albumin (g/dL) | ||||
| <3.5 | 38 | 18 | 20 | .832 |
| ≥3.5 | 49 | 22 | 27 | |
| Corrected Ca (mmol/L) | ||||
| <2.75 | 58 | 26 | 32 | .469 |
| ≥2.75 | 29 | 14 | 15 | |
| sIL‐2R (U/mL) | ||||
| ≤20 000 | 29 | 13 | 16 | .536 |
| >20 000 | 56 | 26 | 30 | |
| Not tested | 2 | 1 | 1 | |
| Regimen of chemotherapy | ||||
| VCAP‐AMP‐VECP | 17 | 5 | 12 | .223 |
| CHOP/CHOP‐like | 42 | 20 | 22 | |
| Etoposide | 11 | 5 | 6 | |
| Others | 9 | 7 | 2 | |
| Untreated | 8 | 3 | 5 | |
| Mogamulizumab | ||||
| − | 24 | 10 | 14 | .400 |
| + | 63 | 30 | 33 | |
| Stem cell transplantation | ||||
| − | 79 | 38 | 41 | .192 |
| + | 8 | 2 | 6 | |
| ATLL‐PI | ||||
| Low | 11 | 4 | 7 | .934 |
| Intermediate | 37 | 17 | 20 | |
| High | 27 | 13 | 14 | |
| Unevaluable | 12 | 6 | 6 | |
| JCOG‐PI | ||||
| Moderate | 30 | 12 | 18 | .280 |
| High | 57 | 28 | 29 | |
| Follow‐up period (month) | ||||
| Median (range) | 7.7 (0.2‐64) | 7.6 (0.2‐50.7) | 10.0 (0.2‐64.0) | |
P values are calculated by two‐sided Fisher's exact test.
Abbreviations: ATLL‐PI, ATLL Prognostic Index; CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; JCOG‐PI, Japan Clinical Oncology Group‐Prognostic Index; LDH, lactate dehydrogenase; PS, performance status; sIL‐2R, soluble interleukin 2 receptor; VCAP‐AMP‐VECP, vincristine, cyclophosphamide, doxorubicin, ranimustine, vindesine, carboplatin, etoposide, and prednisone; WBC, white blood cell.